ストックスクリーナーアプリを入手
441.20
1.27%
5.55
前日終値:
$435.65
開ける：
$441.55
24時間の取引高:
1.03M
Relative Volume:
0.71
時価総額：
$112.22B
収益：
$12.07B
当期純損益:
$3.95B
株価収益率:
28.77
EPS:
15.3349
ネットキャッシュフロー:
$3.19B
1週間 パフォーマンス:
+1.13%
1か月 パフォーマンス:
-4.60%
6か月 パフォーマンス:
+5.85%
1年 パフォーマンス:
-9.79%
1日の値動き範囲:
$437.58
$443.90
1週間の範囲:
$431.15
$447.82
52週間の値動き範囲:
$362.50
$510.77
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | アップグレード | Maxim Group | Hold → Buy |
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-03-10 | 繰り返されました | Oppenheimer | Outperform |
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
GF Fund Management CO. LTD. Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lifted by Asset Management One Co. Ltd. - MarketBeat
Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models - Insider Monkey
Lightning round: Buy Vertex Pharmaceuticals - MSN
Lightning Round: Buy Vertex Pharmaceuticals - CNBC
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex (VRTX) director receives new deferred stock unit grant - Stock Titan
VRTX Stock Quote Price and Forecast - CNN
Vertex (NASDAQ: VRTX) director granted 107 deferred stock units as equity pay - Stock Titan
Vertex (VRTX) board member receives deferred stock unit award - Stock Titan
Vertex Pharma stock (US92532F1003): Is cystic fibrosis dominance still enough for long-term upside? - AD HOC NEWS
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Mirae Asset Global Investments Co. Ltd. - MarketBeat
KBC Group NV Acquires 7,518 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Vertex’s IgAN drug outlook strengthens on positive phase 3 data - S&P Global
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Is Vertex Pharmaceuticals' Empire in Trouble? - AOL.com
Is Vertex Pharmaceuticals' Empire in Trouble? - The Motley Fool
Vertex Pharmaceuticals Incorporated : 2025 Data Summary - marketscreener.com
Vertex price returns lowerForecast today16-04-2026 - Economies.com
Morgan Stanley Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Lbp Am Sa Acquires 22,918 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (STU:VX1) Stock Price & 30 Year Financial Data - GuruFocus
Vertex Pharmaceuticals: Solid CF Franchise and Emerging Pipeline Support Buy Rating and Premium Valuation - TipRanks
Zealand Pharma appoints US-based investor relations head - medwatch.com
5 biopharma M&A deals where the workforce was the prize - BioSpace
Vertex Sues Former Exec To Block Move To Rival - Law360
Baillie Gifford Trims Vertex Pharmaceuticals Stake - National Today
15,717 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Third View Private Wealth LLC - MarketBeat
Massachusetts Financial Services Co. MA Sells 291,226 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baillie Gifford & Co. Has $91.17 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Argenx and Vertex Pharmaceuticals named BofA top biotech picks for 2026 - Investing.com UK
Hardman Johnston Global Advisors LLC Sells 15,346 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Andrew Hill Investment Advisors Inc. - MarketBeat
Sumitomo Mitsui Trust Group Reduces Vertex Pharmaceuticals Stake - National Today
Robeco Institutional Asset Management B.V. Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley - Yahoo Finance
Halozyme Vertex Hypercon Deal Opens New Royalty And Growth Pathways - Sahm
4,828 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Fiduciary Alliance LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Promising Biotech Stocks To Follow TodayApril 10th - MarketBeat
Vertex Pharmaceuticals (VRTX) Analyst Rating Update: Price Targe - GuruFocus
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $612 - Moomoo
RBC Trims Price Target on Vertex Pharmaceuticals to $541 From $543, Keeps Outperform Rating - marketscreener.com
What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report - Yahoo Finance
Vertex licenses Halozyme’s Hypercon platform in $15 million deal - Новости GxP
V Square Quantitative Management LLC Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
OFI Invest Asset Management Buys 68,832 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
0.61%
3.27%
大文字化:
|
ボリューム (24 時間):